We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Jakafi is approved for use in patients with two types of cancers, myelofibrosis and polycythemia vera. Incyte forecast Jakafi sales in 2025 to be between $2.93 billion and $2.98 billion. Sales of ...

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is ...

INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.

R Squared Ltd bought a new position in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the fourth quarter, ...

Incyte shares (NASDAQ:INCY) saw their price target increased by TD Cowen from $86.00 to $88.00, with the firm maintaining a ...